The Cole Foundation continues

to support the Montreal Medical Research Community and the Montreal Theatre Community.

Cole Foundation commits an additional $750,000 to support research into the fight against pediatric and young adult leukemia & lymphoma

Montreal, May 5, 2017
This year, in continuing the tradition of past years, the Cole Foundation will be
offering sixteen new fellowship grants for a total funding value of $750,000 to be
disbursed over the course of the next two years towards research into the fight
against pediatric and young adult leukemia and lymphoma.

Since the inception of these grants eleven years ago and including this year, the
Cole Foundation will have contributed close to $11 million to more than 165
researchers in laboratories and hospitals situated in the Greater Montreal area
through collaborations with l’Université de Montréal; McGill University; and INRS –
Institut Armand-Frappier Research Centre.

“The Cole Foundation is committed to helping to develop the next generation of
researchers, said Barry Cole, President of the foundation. The objective of our
efforts to support the medical faculties at the Université de Montréal and McGill
University, as well as the Institut national de recherche scientifique (INRS) – Institut
Armand-Frappier is to create a “Centre of Expertise” in Montreal for research into
the fight against pediatric and young adult leukemia and lymphoma.”

“Thanks to the Cole Foundation’s involvement, we have succeeded in pooling the
strengths of the city’s universities in research in pediatric and young-adult
hematology and oncology and, by so doing, have made Montreal a true centre of
excellence of research into leukemia and blood cancers. Through their efforts, the
Foundation contributes to this success of which we can all be very proud, “said Dr.
Hélène Boisjoly, dean of the Faculty of Medicine of Université de Montréal.

“The continued support of the Cole Foundation to McGill and Québec’s other
leading institutions enables our early-career scientists to be at the forefront of
pediatric leukemia research,” said Dr. David Eidelman, Vice-Principal (Health
Affairs) and Dean of Medicine at McGill University. “This is a wonderful example of
how philanthropic collaboration fosters discovery for the benefit of the communities
we serve.”

In connection with the new round of grants, the Cole Foundation is organizing a
day of discussions on the state of research in the field of pediatric cancer, to be
held on May 5 this year at the Université de Montréal. The day-long event will
include a special presentation by Dr Greg Armstrong MD, MSCE from the St. Jude
Children’s Research Hospital in Memphis, Tennessee. His talk is entitled “The
Lifetime Impact of Cancer and Cancer Therapy “. All of the members of the
Montreal medical research community will be invited.

About the Cole Foundation

The Cole Foundation offers two-year fellowships to clinical, doctoral and
postdoctoral graduate scientists dedicated to research in leukemia and leukemiarelated
diseases in children and young adults. Through its fellowships, the Cole
Foundation has committed more than $10 million to support leukemia researchers
in Greater Montreal laboratories and hospitals. The Cole Foundation was created
in 1980 by the late businessman John N. (Jack) Cole to support Montreal-based
research in pediatric oncology and hematology. He established the Penny Cole
Laboratory at the Montreal Children’s Hospital and the Jack Cole Chair in Pediatric
Oncology and Hematology at McGill University.

Cole Foundation Research Fellowships (2017-2019)

Université de Montréal

Elodie Da Costa, PhD program
Project title: Targeting histone acetylation and oncogenes in pediatric leukemia

Erlinda Fernández Díaz, PhD program
Project title: Telomere defects induced by IDH1/2 mutations associated to acute myeloid leukemia

Ema Flores-Díaz, PhD program
Project title: Targeting key vulnerabilities of pre-Leukemic Stem Cells in T-cell
Acute Lymphoblastic Leukemia

Ryan Killoran, Post PhD program
Project title: Characterization of Dimer-Activated MLL in Acute Leukemia

Shirin Lak, PhD program
Project title: Enhancing antigen specific T cell function through co-signaling modulation

Mathieu Neault, Post PhD program
Project title: A Genome-Wide CRISPR/cas9 Screen for the Identification of Novel Therapeutic Targets in Acute Megakaryoblastic Leukemia

Linnéa Olofsson, Post PhD program
Project title: Understanding and exploiting Fbw7 genetic insufficiency in leukemia
and lymphoma

Guillaume Richard-Carpentier, Clinician program
Project title: Identification and Validation of New Prognostic Markers to Improve
Risk Stratification in Intermediate Risk Acute Myeloid Leukemia

Laura Simon, PhD program
Project title: Chemogenomics of RUNX1-mutated Acute Myeloid Leukemia

Damehan Tchelougou, PhD program
Project title: ASXL family of transcription co-factors in Childhood leukemia

Elisa Tomellini, Post PhD program
Project title: Expansion of human hematopoietic stem cells: improving and
understanding self-renewal from the bench to the optimal cord graf

McGill University

Alexandre Benoit, PhD program
Project title: The Role of mutated Ras-associating proteins and STAT6 in RCHOP
resistant DLBCL

Meaghan Boileau, PhD program
Project title: Identification of bioactive molecules that target acute myeloid
leukemia stem cells

Martin Karam, PhD program
Project title: Deciphering the role of the zing finger protein POGZ during
hematopoiesis and pediatric Acute Myeloid Leukemia

Mingyi Vincent Luo, PhD program
Project title: Deciphering the role of deubiquitinases in B-cells and Diffuse Large
B-cell lymphoma

Abba Malina, Post PhD program
Project title: Determining clinically relevant genetic mutations that elicit resistance
to chemotherapy in Burkitts lymphoma using CRISPR/Cas9

Jutta Steinberger, Post PhD program
Project title: Targeting MYC expression in lymphoma and leukemia

Faculté de médecine de l’Université de Montréal:
McGill Faculty of Medicine:
INRS–Institut Armand-Frappier:

This entry was posted in Events, Press Releases on May 5, 2017.